News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 573
- Sources here
- 22
- Companies here
- 9
Search results
Stored financial headlines
Active search
573 matching headlines
Ticker or company: IOMMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Zimmer Biomet Holdings (ZBH) Following Its Beat And Guidance Lift, Is The Valuation Catching Up?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Zimmer Biomet Holdings (ZBH) just paired stronger than expected quarterly results with a guidance increase, as management pointed to solid execution in U.S. hip …
Sharemaestro market context Trend signal started 52 weeks -5.6%Zimmer Biomet (ZBH) Stock Gets Fair Value Bump After Mixed Analyst Views
Zimmer Biomet Holdings (ZBH) has seen its fair value updated by analysts, with some taking a bullish stance due to undervaluation and growth opportunities, while others remain cautious, emphasizing consistent execution and margin stabilization. The company's fair value moved from US$98.70 to approximately US$102.19, …
Sharemaestro market context Trend signal started 52 weeks -5.6%Biomarin Pharma earnings beat by $0.25, revenue topped estimates
Biomarin Pharma (NASDAQ: BMRN) reported strong second-quarter results, beating analyst estimates for both earnings per share (EPS) and revenue. The company posted an EPS of $1.20, exceeding the $0.95 consensus, and revenue of $990 million, higher than the $939.37 million estimate. Its stock has …
BMRN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.0%
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q2 revenue up, profit down after Amicus acquisition
BioMarin Pharmaceutical Inc. reported a significant increase in Q2 2026 total revenues to $989.7 million, up from $825.4 million in 2025, primarily due to strong performance from VOXZOGO, PALYNZIQ, and newly acquired products GALAFOLD and POMBILITI + OPFOLDA. Despite revenue growth, net income fell …
BMRN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.0%
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.20 per Share, vs. FactSet Est of $0.95
BioMarin Pharmaceutical Inc. (BMRN) reported Q2 adjusted EPS of $1.20 per share, surpassing the FactSet estimate of $0.95. The company also announced Q2 revenue of $990.0 million, exceeding the FactSet estimate of $932.0 million, and provided updated earnings guidance for the full year 2026. …
BMRN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.0%
BioMarin earnings on deck as flagship drug faces competition
BioMarin Pharmaceutical Inc. is set to report second-quarter earnings, with analysts expecting 95 cents per share on $939.2 million in revenue, an increase from the previous quarter. The upcoming earnings call will likely focus on the competitive landscape for its top drug, VOXZOGO, which …
BMRN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.0%
BioMarin Pharmaceutical Q2 Earnings Call Highlights
BioMarin Pharmaceutical's Q2 revenue approached $1 billion, a 20% increase year-over-year, driven by its rare-disease portfolio and the Amicus acquisition. The company raised its full-year guidance for revenue, VOXZOGO revenue, and non-GAAP EPS, projecting significant growth from Amicus therapies and VOXZOGO becoming a $1 …
BMRN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.0%
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash
Generate Biomedicines reported its second-quarter 2026 results, showing $6.3 million in collaboration revenue and a net loss of $67.3 million. The company held $457.4 million in cash, which is expected to fund operations into the first half of 2028, and highlighted advancement in multiple …
GENB
main company
Sharemaestro market context
Stored weekly price path
25 weeks +23.6%
Zimmer Biomet Holdings, Inc. Stock 12‑Month Price Target Raised to $104.9, Implies 7% Upside
Zimmer Biomet Holdings, Inc.'s average price target has been increased to $104.9, up from $104.26, according to 20 analysts. This updated target suggests a potential 7% upside based on the Aug. 5 closing price. The consensus rating among 29 analysts remains a "Buy," with …
ZBH
main company
Sharemaestro market context
Trend signal started
52 weeks -5.6%
JPMorgan Adjusts Price Target on Zimmer Biomet to $117 From $95
JPMorgan has raised its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $117 from $95. This adjustment was reported on August 6, 2026, at 12:02 pm EDT. The article also notes several other analyst adjustments for Zimmer Biomet on the same day.
ZBH
main company
Sharemaestro market context
Trend signal started
52 weeks -5.6%
UBS Adjusts Price Target on Zimmer Biomet to $120 From $115, Maintains Buy Rating
UBS has increased its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $120 from $115, while reaffirming a Buy rating on the stock. This adjustment comes amidst other analyst revisions for Zimmer Biomet on the same day, indicating active re-evaluation of the company's …
ZBH
main company
Sharemaestro market context
Trend signal started
52 weeks -5.6%
Zimmer Biomet sales force revamp going better than expected, CEO says
Zimmer Biomet's CEO Ivan Tornos announced that the company's transition to a fully dedicated sales force is progressing better than anticipated, leading to increased sales and earnings expectations for 2026. The restructuring, involving a shift of 2,500 U.S. sales personnel to dedicated specialists, has …
ZBH
main company
Sharemaestro market context
Trend signal started
52 weeks -5.6%
Deutsche Bank Adjusts Zimmer Biomet Price Target to $98 From $88, Maintains Hold Rating
Deutsche Bank has adjusted its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $98, up from $88, while maintaining a "Hold" rating on the stock. This update reflects recent market activity and analyst assessments. The article also notes other analyst revisions for Zimmer …
ZBH
main company
Sharemaestro market context
Trend signal started
52 weeks -5.6%
Generate Biomedicines Shares Fall Following Q2 Financial Results
Generate Biomedicines (GENB) shares dropped by 4.6% after the company announced its Q2 financial results, indicating a wider loss than expected. The full details of the financial performance are behind a premium paywall.
GENB
main company
Sharemaestro market context
Stored weekly price path
25 weeks +23.6%
Generate Biomedicines (Nasdaq:GENB) - Stock Analysis
Generate Biomedicines (GENB) is utilizing machine learning for drug discovery and development, holding a market cap of US$1.8 billion. While revenue is projected to grow significantly, the company is currently unprofitable and faces risks such as declining earnings forecasts and a cash runway of …
GENB
main company
Sharemaestro market context
Stored weekly price path
25 weeks +23.6%
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion, a clinical-stage diabetes and obesity company, reported its second quarter 2026 financial results, highlighting ongoing enrollment in Phase II clinical trials for insulin-deficient Type 2 diabetes and Type 2 diabetes patients on GLP-1 RA therapy, with data expected in Q1 and Q2 …
BMEA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -27.9% · Next-week setup negative 44.3%
BioMea Q2 Loss Shrinks; Data From Phase 2 Trials For Icovamenib In Diabetes Expected In '27
(RTTNews) - Biomea Fusion, Inc. (BMEA) recorded a narrowed loss for the second quarter ended June 30, 2026, attributable to lower operating expenses. The biotech company also provided various pipeline updates. Company Profile Biomea is a clinical-stage biotechnology company developing oral small-molecule therapies for …
BMEA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -27.9% · Next-week setup negative 44.3%